Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer.
about
New advances in targeted gastric cancer treatmentCurrent Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical ApplicationNimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivomicroRNA-664 enhances proliferation, migration and invasion of lung cancer cellsThe emerging role of nimotuzumab in the treatment of non-small cell lung cancer.Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab.Monoclonal antibodies as effective therapeutic agents for solid tumors.Trial Watch: Monoclonal antibodies in cancer therapyRandomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancerS-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 TrialCharacterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy.EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab.Pharmacokinetics and Biodistribution Study of 7A7 Anti-Mouse Epidermal Growth Factor Receptor Monoclonal Antibody and Its F(ab')(2) Fragment in an Immunocompetent Mouse ModelEnhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status.A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancerNimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial.Antibody h-R3-dendrimer mediated siRNA has excellent endosomal escape and tumor targeted delivery ability, and represents efficient siPLK1 silencing and inhibition of cell proliferation, migration and invasion.Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis.Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experienceNimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity.Nimotuzumab in pediatric glioma.Nimotuzumab for pediatric diffuse intrinsic pontine gliomas.Targeting the epidermal growth factor receptor in solid tumor malignancies.Clinical management of advanced gastric cancer: the role of new molecular drugs.Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancerNimotuzumab enhances radiation sensitivity of NSCLC H292 cells in vitro by blocking epidermal growth factor receptor nuclear translocation and inhibiting radiation-induced DNA damage repairActive antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant.Semimechanistic model to characterize nonlinear pharmacokinetics of nimotuzumab in patients with advanced breast cancer.The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neckA phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors.Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients.Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy.Multiple dose toxicity study of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 intravenously administered to Cercopithecus aethiops sabaeus monkeys.Treatment Outcomes of 257 Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Nimotuzumab Plus Intensity-Modulated Radiotherapy with or without Chemotherapy: A Single-Institution Experience.Efficacy and Safety of Nimotuzumab Plus Radiotherapy With or Without Cisplatin-Based Chemotherapy in an Elderly Patient Subgroup (Aged 60 and Older) With Nasopharyngeal Carcinoma.Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis.Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma.Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549 in vitro.
P2860
Q26738548-A7906097-74B6-4CE8-A128-63CB0DD31B0EQ26765941-8B3177A8-5AE6-4671-BF21-82F05A293621Q27853322-5D72B7C0-FF34-4CDA-A375-299633E1BA67Q33745073-78B13C08-2A0B-43CB-97D1-28769470605AQ34343043-43A1D552-D98A-4850-BFB1-386390631FA8Q34382797-92F95B45-DC99-4C03-ADF4-310BC6894900Q34586272-D50A0941-F05E-430D-B836-A95CBBE6CF3BQ35857856-35ED6F78-69AB-4E2B-85DD-3C16F8D4BA72Q36038408-E28AB28A-9773-416E-A4E9-5393E9E79B84Q36065419-CE829A37-508E-46B5-9610-1F0685C1F06EQ36194219-51B9B43D-FA08-487E-9FD1-51F411D39D87Q36216991-4CFF95E6-617C-46A1-9746-022B79D3E6C9Q36302347-52DA4F7A-B6A8-4F3E-AFF3-7770F1F53C33Q36440219-70BC8011-1D74-4F0F-837B-C5AC01E08286Q36484536-85B68F9C-0F4F-4B1D-AD38-A413FDEC4508Q36656070-0C7A556A-4176-4766-B7DE-9E6BCB4192D3Q36801223-6A943D40-772B-4FC6-AAFA-376ED0AC1748Q37046458-4D9530D3-45F9-436F-9045-7539DB166504Q37269328-8B9E8063-F40F-445C-9947-4F7B5D8EFD51Q37362948-57680C84-135D-4310-AB43-EE154F1933F6Q37558534-417A08AB-A8C0-4C88-95AF-16D9C2FB28DFQ37630569-3555038B-783C-4D0F-B141-14A3E987524CQ37822466-E6D0713F-2D96-481F-85C9-D998EEE87650Q37990044-6472E78D-AEE1-416F-961E-CD3101C06445Q38263841-9D4F65E9-C9CE-4693-A15B-75F02715634CQ39139857-22839608-E82D-4895-8689-89646B6A8708Q39802972-869A5C68-6579-4DD4-8FE5-8F0FD3550B2AQ40255826-9C59F9D3-41DC-4216-B2AA-70B3E9FC0401Q41245735-850F69F4-01E9-44EB-876C-29C3F0EC4F91Q41513098-CCC532F0-DBE3-4FA0-941E-C47CF28CBFCAQ43439165-04360445-6708-4391-82B1-4173E3F719FAQ44021954-78AAD681-CF2F-43AF-A500-09862A0B0B05Q45357051-C1189542-3A06-406F-BF8E-0E3919C0B321Q47193015-1FA069CF-E270-488F-ACC3-AA8E6488F810Q47277455-F45ADED0-8D47-4843-9940-981936ADE5A7Q47301004-D2F3F9F4-8940-4156-8707-326D7A17AD54Q50095911-FB4A38EF-D39C-416B-A12E-AF677C427067Q50311224-3CD0D97A-8353-4A6A-8DB7-0F151B36F695Q50939594-54BB5538-2D41-4F67-9E44-CE193BAFC2C0Q52725862-4713E5CE-EA17-43D1-A174-A02C084354CD
P2860
Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Pharmacological evaluation of ...... ced epithelial-derived cancer.
@en
type
label
Pharmacological evaluation of ...... ced epithelial-derived cancer.
@en
prefLabel
Pharmacological evaluation of ...... ced epithelial-derived cancer.
@en
P2093
P1476
Pharmacological evaluation of ...... ced epithelial-derived cancer.
@en
P2093
Agustín Lage
Alejandro Perera
Elia Neninger
Franz Torres
Leonel Torres
María E Solano
Mauricio Catalá
Normando Iznaga
Olga Torres
Rolando Pérez
P304
P356
10.1097/00002371-200303000-00006
P577
2003-03-01T00:00:00Z